Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland
Identifieur interne : 002021 ( Istex/Corpus ); précédent : 002020; suivant : 002022Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland
Auteurs : Christophe Le Tourneau ; Albiruni R A. Razak ; Christine Levy ; Valentin Calugaru ; Olivier Galatoire ; Rémi Dendale ; Laurence Desjardins ; Hui K. GanSource :
- British Journal of Ophthalmology [ 0007-1161 ] ; 2011-11.
English descriptors
- KwdEn :
- Adenoid, Adjuvant, Adjuvant chemotherapy, Apoptosis, Apoptosis proteins, Carcinoma, Cell carcinoma, Cell lines, Chemotherapy, Cisplatin, Clin, Clin cancer, Clinical outcome, Egfr, Epidermal, Epidermal growth factor receptor, Epithelial, Extracellular, Gland, Growth factor, Her2, Imatinib, Imatinib mesylate, Immunohistochemical study, Inhibitor, Institut curie, Kinase, Lacrimal, Lacrimal gland, Lacrimal gland adenoid, Matrix, Metastasis, Metastatic, Metastatic disease, Mutation, Neck cancer, Neoadjuvant, Neoadjuvant chemotherapy, Oncogene homologue, Oncol, Ophthalmol, Oral pathol, Partial response, Pathol, Pathway, Perineural, Perineural invasion, Postoperative radiotherapy, Prognostic, Radiotherapy, Receptor, Recurrence, Retrospective data, Salivary, Salivary adenoid, Salivary gland, Salivary gland adenoid, Salivary gland carcinoma, Salivary gland carcinomas, Salivary glands, Solid tumors, Systemic therapy, Tumour, Vegf, Vegf expression.
- Teeft :
- Adenoid, Adjuvant, Adjuvant chemotherapy, Apoptosis, Apoptosis proteins, Carcinoma, Cell carcinoma, Cell lines, Chemotherapy, Cisplatin, Clin, Clin cancer, Clinical outcome, Egfr, Epidermal, Epidermal growth factor receptor, Epithelial, Extracellular, Gland, Growth factor, Her2, Imatinib, Imatinib mesylate, Immunohistochemical study, Inhibitor, Institut curie, Kinase, Lacrimal, Lacrimal gland, Lacrimal gland adenoid, Matrix, Metastasis, Metastatic, Metastatic disease, Mutation, Neck cancer, Neoadjuvant, Neoadjuvant chemotherapy, Oncogene homologue, Oncol, Ophthalmol, Oral pathol, Partial response, Pathol, Pathway, Perineural, Perineural invasion, Postoperative radiotherapy, Prognostic, Radiotherapy, Receptor, Recurrence, Retrospective data, Salivary, Salivary adenoid, Salivary gland, Salivary gland adenoid, Salivary gland carcinoma, Salivary gland carcinomas, Salivary glands, Solid tumors, Systemic therapy, Tumour, Vegf, Vegf expression.
Abstract
Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.
Url:
DOI: 10.1136/bjo.2010.192351
Links to Exploration step
ISTEX:A98138A4D9375D8FFEF3D33B382D44F5404C7005Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title><author><name sortKey="Le Tourneau, Christophe" sort="Le Tourneau, Christophe" uniqKey="Le Tourneau C" first="Christophe" last="Le Tourneau">Christophe Le Tourneau</name><affiliation><mods:affiliation>Département d'Oncologie Médicale, Institut Curie, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: christophe.letourneau@curie.net</mods:affiliation></affiliation></author><author><name sortKey="Razak, Albiruni R A" sort="Razak, Albiruni R A" uniqKey="Razak A" first="Albiruni R A" last="Razak">Albiruni R A. Razak</name><affiliation><mods:affiliation>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Levy, Christine" sort="Levy, Christine" uniqKey="Levy C" first="Christine" last="Levy">Christine Levy</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Calugaru, Valentin" sort="Calugaru, Valentin" uniqKey="Calugaru V" first="Valentin" last="Calugaru">Valentin Calugaru</name><affiliation><mods:affiliation>Département de Radiothérapie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galatoire, Olivier" sort="Galatoire, Olivier" uniqKey="Galatoire O" first="Olivier" last="Galatoire">Olivier Galatoire</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Rémi" last="Dendale">Rémi Dendale</name><affiliation><mods:affiliation>Département de Radiothérapie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Desjardins, Laurence" sort="Desjardins, Laurence" uniqKey="Desjardins L" first="Laurence" last="Desjardins">Laurence Desjardins</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K" last="Gan">Hui K. Gan</name><affiliation><mods:affiliation>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A98138A4D9375D8FFEF3D33B382D44F5404C7005</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1136/bjo.2010.192351</idno><idno type="url">https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002021</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002021</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title><author><name sortKey="Le Tourneau, Christophe" sort="Le Tourneau, Christophe" uniqKey="Le Tourneau C" first="Christophe" last="Le Tourneau">Christophe Le Tourneau</name><affiliation><mods:affiliation>Département d'Oncologie Médicale, Institut Curie, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: christophe.letourneau@curie.net</mods:affiliation></affiliation></author><author><name sortKey="Razak, Albiruni R A" sort="Razak, Albiruni R A" uniqKey="Razak A" first="Albiruni R A" last="Razak">Albiruni R A. Razak</name><affiliation><mods:affiliation>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Levy, Christine" sort="Levy, Christine" uniqKey="Levy C" first="Christine" last="Levy">Christine Levy</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Calugaru, Valentin" sort="Calugaru, Valentin" uniqKey="Calugaru V" first="Valentin" last="Calugaru">Valentin Calugaru</name><affiliation><mods:affiliation>Département de Radiothérapie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galatoire, Olivier" sort="Galatoire, Olivier" uniqKey="Galatoire O" first="Olivier" last="Galatoire">Olivier Galatoire</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Rémi" last="Dendale">Rémi Dendale</name><affiliation><mods:affiliation>Département de Radiothérapie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Desjardins, Laurence" sort="Desjardins, Laurence" uniqKey="Desjardins L" first="Laurence" last="Desjardins">Laurence Desjardins</name><affiliation><mods:affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K" last="Gan">Hui K. Gan</name><affiliation><mods:affiliation>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">British Journal of Ophthalmology</title><title level="j" type="abbrev">Br J Ophthalmol</title><idno type="ISSN">0007-1161</idno><idno type="eISSN">1468-2079</idno><imprint><publisher>BMJ Publishing Group Ltd.</publisher><pubPlace>BMA House, Tavistock Square, London, WC1H 9JR</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1483">1483</biblScope></imprint><idno type="ISSN">0007-1161</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0007-1161</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoid</term><term>Adjuvant</term><term>Adjuvant chemotherapy</term><term>Apoptosis</term><term>Apoptosis proteins</term><term>Carcinoma</term><term>Cell carcinoma</term><term>Cell lines</term><term>Chemotherapy</term><term>Cisplatin</term><term>Clin</term><term>Clin cancer</term><term>Clinical outcome</term><term>Egfr</term><term>Epidermal</term><term>Epidermal growth factor receptor</term><term>Epithelial</term><term>Extracellular</term><term>Gland</term><term>Growth factor</term><term>Her2</term><term>Imatinib</term><term>Imatinib mesylate</term><term>Immunohistochemical study</term><term>Inhibitor</term><term>Institut curie</term><term>Kinase</term><term>Lacrimal</term><term>Lacrimal gland</term><term>Lacrimal gland adenoid</term><term>Matrix</term><term>Metastasis</term><term>Metastatic</term><term>Metastatic disease</term><term>Mutation</term><term>Neck cancer</term><term>Neoadjuvant</term><term>Neoadjuvant chemotherapy</term><term>Oncogene homologue</term><term>Oncol</term><term>Ophthalmol</term><term>Oral pathol</term><term>Partial response</term><term>Pathol</term><term>Pathway</term><term>Perineural</term><term>Perineural invasion</term><term>Postoperative radiotherapy</term><term>Prognostic</term><term>Radiotherapy</term><term>Receptor</term><term>Recurrence</term><term>Retrospective data</term><term>Salivary</term><term>Salivary adenoid</term><term>Salivary gland</term><term>Salivary gland adenoid</term><term>Salivary gland carcinoma</term><term>Salivary gland carcinomas</term><term>Salivary glands</term><term>Solid tumors</term><term>Systemic therapy</term><term>Tumour</term><term>Vegf</term><term>Vegf expression</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adenoid</term><term>Adjuvant</term><term>Adjuvant chemotherapy</term><term>Apoptosis</term><term>Apoptosis proteins</term><term>Carcinoma</term><term>Cell carcinoma</term><term>Cell lines</term><term>Chemotherapy</term><term>Cisplatin</term><term>Clin</term><term>Clin cancer</term><term>Clinical outcome</term><term>Egfr</term><term>Epidermal</term><term>Epidermal growth factor receptor</term><term>Epithelial</term><term>Extracellular</term><term>Gland</term><term>Growth factor</term><term>Her2</term><term>Imatinib</term><term>Imatinib mesylate</term><term>Immunohistochemical study</term><term>Inhibitor</term><term>Institut curie</term><term>Kinase</term><term>Lacrimal</term><term>Lacrimal gland</term><term>Lacrimal gland adenoid</term><term>Matrix</term><term>Metastasis</term><term>Metastatic</term><term>Metastatic disease</term><term>Mutation</term><term>Neck cancer</term><term>Neoadjuvant</term><term>Neoadjuvant chemotherapy</term><term>Oncogene homologue</term><term>Oncol</term><term>Ophthalmol</term><term>Oral pathol</term><term>Partial response</term><term>Pathol</term><term>Pathway</term><term>Perineural</term><term>Perineural invasion</term><term>Postoperative radiotherapy</term><term>Prognostic</term><term>Radiotherapy</term><term>Receptor</term><term>Recurrence</term><term>Retrospective data</term><term>Salivary</term><term>Salivary adenoid</term><term>Salivary gland</term><term>Salivary gland adenoid</term><term>Salivary gland carcinoma</term><term>Salivary gland carcinomas</term><term>Salivary glands</term><term>Solid tumors</term><term>Systemic therapy</term><term>Tumour</term><term>Vegf</term><term>Vegf expression</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>adenoid</json:string><json:string>carcinoma</json:string><json:string>lacrimal</json:string><json:string>tumour</json:string><json:string>metastatic</json:string><json:string>salivary</json:string><json:string>oncol</json:string><json:string>chemotherapy</json:string><json:string>lacrimal gland</json:string><json:string>egfr</json:string><json:string>clin</json:string><json:string>pathol</json:string><json:string>receptor</json:string><json:string>ophthalmol</json:string><json:string>pathway</json:string><json:string>her2</json:string><json:string>imatinib</json:string><json:string>kinase</json:string><json:string>mutation</json:string><json:string>salivary glands</json:string><json:string>salivary gland</json:string><json:string>metastasis</json:string><json:string>adjuvant</json:string><json:string>neoadjuvant</json:string><json:string>epidermal</json:string><json:string>vegf</json:string><json:string>cisplatin</json:string><json:string>radiotherapy</json:string><json:string>extracellular</json:string><json:string>salivary adenoid</json:string><json:string>prognostic</json:string><json:string>epithelial</json:string><json:string>apoptosis</json:string><json:string>perineural</json:string><json:string>oral pathol</json:string><json:string>salivary gland carcinomas</json:string><json:string>adjuvant chemotherapy</json:string><json:string>inhibitor</json:string><json:string>gland</json:string><json:string>lacrimal gland adenoid</json:string><json:string>clin cancer</json:string><json:string>systemic therapy</json:string><json:string>growth factor</json:string><json:string>neoadjuvant chemotherapy</json:string><json:string>postoperative radiotherapy</json:string><json:string>cell carcinoma</json:string><json:string>epidermal growth factor receptor</json:string><json:string>perineural invasion</json:string><json:string>cell lines</json:string><json:string>recurrence</json:string><json:string>matrix</json:string><json:string>solid tumors</json:string><json:string>institut curie</json:string><json:string>neck cancer</json:string><json:string>salivary gland carcinoma</json:string><json:string>metastatic disease</json:string><json:string>imatinib mesylate</json:string><json:string>retrospective data</json:string><json:string>oncogene homologue</json:string><json:string>partial response</json:string><json:string>clinical outcome</json:string><json:string>vegf expression</json:string><json:string>salivary gland adenoid</json:string><json:string>apoptosis proteins</json:string><json:string>immunohistochemical study</json:string></teeft></keywords><author><json:item><name>Christophe Le Tourneau</name><affiliations><json:string>Département d'Oncologie Médicale, Institut Curie, Paris, France</json:string><json:string>E-mail: christophe.letourneau@curie.net</json:string></affiliations></json:item><json:item><name>Albiruni R A Razak</name><affiliations><json:string>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Christine Levy</name><affiliations><json:string>Département d'Ophtalmologie, Institut Curie, Paris, France</json:string></affiliations></json:item><json:item><name>Valentin Calugaru</name><affiliations><json:string>Département de Radiothérapie, Institut Curie, Paris, France</json:string></affiliations></json:item><json:item><name>Olivier Galatoire</name><affiliations><json:string>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</json:string></affiliations></json:item><json:item><name>Rémi Dendale</name><affiliations><json:string>Département de Radiothérapie, Institut Curie, Paris, France</json:string></affiliations></json:item><json:item><name>Laurence Desjardins</name><affiliations><json:string>Département d'Ophtalmologie, Institut Curie, Paris, France</json:string></affiliations></json:item><json:item><name>Hui K Gan</name><affiliations><json:string>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Adenoid cystic carcinoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lacrimal gland</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>targeted therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chemotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>microbiology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment medical</value></json:item></subject><articleId><json:string>bjophthalmol192351</json:string></articleId><arkIstex>ark:/67375/NVC-5FR75XLX-Z</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>review-article</json:string></originalGenre><abstract>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</abstract><qualityIndicators><score>9.088</score><pdfWordCount>6154</pdfWordCount><pdfCharCount>41439</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>174</abstractWordCount><abstractCharCount>1213</abstractCharCount><keywordCount>6</keywordCount></qualityIndicators><title>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title><pmid><json:string>21183517</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>British Journal of Ophthalmology</title><language><json:string>unknown</json:string></language><issn><json:string>0007-1161</json:string></issn><eissn><json:string>1468-2079</json:string></eissn><publisherId><json:string>bjo</json:string></publisherId><volume>95</volume><issue>11</issue><pages><first>1483</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>8920</json:string><json:string>2010-12-22</json:string></date><geogName></geogName><orgName><json:string>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia Surgery</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Christophe Le Tourneau</json:string><json:string>Cisplatin</json:string><json:string>Paris Cedex</json:string><json:string>Olivier Galatoire</json:string><json:string>In</json:string><json:string>Christine Levy</json:string><json:string>Of</json:string><json:string>The</json:string><json:string>Remi Dendale</json:string><json:string>Valentin Calugaru</json:string><json:string>Phase</json:string><json:string>Laurence Desjardins</json:string></persName><placeName><json:string>Paris</json:string><json:string>France</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-5FR75XLX-Z</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - ophthalmology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - ophthalmology & optometry</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Neuroscience</json:string><json:string>3 - Cellular and Molecular Neuroscience</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Neuroscience</json:string><json:string>3 - Sensory Systems</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Ophthalmology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2011</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1136/bjo.2010.192351</json:string></doi><id>A98138A4D9375D8FFEF3D33B382D44F5404C7005</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd.</publisher><pubPlace>BMA House, Tavistock Square, London, WC1H 9JR</pubPlace><availability><licence><p>© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2010-12-22</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Christophe</forename><surname>Le Tourneau</surname></persName><email>christophe.letourneau@curie.net</email><affiliation>Département d'Oncologie Médicale, Institut Curie, Paris, France</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Albiruni R A</forename><surname>Razak</surname></persName><affiliation>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Christine</forename><surname>Levy</surname></persName><affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Valentin</forename><surname>Calugaru</surname></persName><affiliation>Département de Radiothérapie, Institut Curie, Paris, France</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Olivier</forename><surname>Galatoire</surname></persName><affiliation>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Rémi</forename><surname>Dendale</surname></persName><affiliation>Département de Radiothérapie, Institut Curie, Paris, France</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Laurence</forename><surname>Desjardins</surname></persName><affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Hui K</forename><surname>Gan</surname></persName><affiliation>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</affiliation></author><idno type="istex">A98138A4D9375D8FFEF3D33B382D44F5404C7005</idno><idno type="ark">ark:/67375/NVC-5FR75XLX-Z</idno><idno type="DOI">10.1136/bjo.2010.192351</idno><idno type="href">bjophthalmol-95-1483.pdf</idno><idno type="article-id">bjophthalmol192351</idno><idno type="PMID">21183517</idno><idno type="local">bjophthalmol;95/11/1483</idno></analytic><monogr><title level="j">British Journal of Ophthalmology</title><title level="j" type="abbrev">Br J Ophthalmol</title><idno type="pISSN">0007-1161</idno><idno type="eISSN">1468-2079</idno><idno type="publisher-id">bjo</idno><idno type="PublisherID-hwp">bjophthalmol</idno><idno type="PublisherID-nlm-ta">Br J Ophthalmol</idno><imprint><publisher>BMJ Publishing Group Ltd.</publisher><pubPlace>BMA House, Tavistock Square, London, WC1H 9JR</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">95</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1483">1483</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010-12-22</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>Adenoid cystic carcinoma</term></item><item><term>lacrimal gland</term></item><item><term>targeted therapy</term></item><item><term>chemotherapy</term></item><item><term>microbiology</term></item><item><term>treatment medical</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-12-22">Created</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="review-article"><front><journal-meta><journal-id journal-id-type="hwp">bjophthalmol</journal-id><journal-id journal-id-type="nlm-ta">Br J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">bjo</journal-id><journal-title>British Journal of Ophthalmology</journal-title><abbrev-journal-title abbrev-type="publisher">Br J Ophthalmol</abbrev-journal-title><abbrev-journal-title>Br J Ophthalmol</abbrev-journal-title><issn pub-type="ppub">0007-1161</issn><issn pub-type="epub">1468-2079</issn><publisher><publisher-name>BMJ Publishing Group Ltd.</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bjophthalmol192351</article-id><article-id pub-id-type="doi">10.1136/bjo.2010.192351</article-id><article-id pub-id-type="other">bjophthalmol;95/11/1483</article-id><article-id pub-id-type="other">bjophthalmol;bjo.2010.192351</article-id><article-id pub-id-type="pmid">21183517</article-id><article-id pub-id-type="other">1483</article-id><article-id pub-id-type="other">bjo.2010.192351</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Le Tourneau</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Razak</surname><given-names>Albiruni R A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Calugaru</surname><given-names>Valentin</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Galatoire</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Dendale</surname><given-names>Rémi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Desjardins</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gan</surname><given-names>Hui K</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Département d'Oncologie Médicale, Institut Curie, Paris, France</aff><aff id="aff2"><label>2</label>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</aff><aff id="aff3"><label>3</label>Département d'Ophtalmologie, Institut Curie, Paris, France</aff><aff id="aff4"><label>4</label>Département de Radiothérapie, Institut Curie, Paris, France</aff><aff id="aff5"><label>5</label>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</aff><aff id="aff6"><label>6</label>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</aff><author-notes><corresp><label>Correspondence to</label> Dr Christophe Le Tourneau, Département d'Oncologie Médicale – Unité d'Investigation Clinique, Institut Curie, 26, rue d'Ulm – 75248 Paris Cedex 05; <email>christophe.letourneau@curie.net</email></corresp></author-notes><pub-date pub-type="epub-original"><day>22</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2010</year></pub-date><volume>95</volume><volume-id pub-id-type="other">95</volume-id><volume-id pub-id-type="other">95</volume-id><issue>11</issue><issue-id pub-id-type="other">bjophthalmol;95/11</issue-id><issue-id pub-id-type="other">11</issue-id><issue-id pub-id-type="other">95/11</issue-id><fpage>1483</fpage><history><date date-type="accepted"><day>4</day><month>12</month><year>2010</year></date></history><permissions><copyright-statement>© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</copyright-statement><copyright-year>2011</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="bjophthalmol-95-1483.pdf"></self-uri><abstract><p>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</p></abstract><kwd-group><kwd>Adenoid cystic carcinoma</kwd><kwd>lacrimal gland</kwd><kwd>targeted therapy</kwd><kwd>chemotherapy</kwd><kwd>microbiology</kwd><kwd>treatment medical</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Christophe</namePart><namePart type="family">Le Tourneau</namePart><affiliation>Département d'Oncologie Médicale, Institut Curie, Paris, France</affiliation><affiliation>E-mail: christophe.letourneau@curie.net</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Albiruni R A</namePart><namePart type="family">Razak</namePart><affiliation>Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Levy</namePart><affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Valentin</namePart><namePart type="family">Calugaru</namePart><affiliation>Département de Radiothérapie, Institut Curie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Galatoire</namePart><affiliation>Département d'Ophtalmologie, Fondation Rothschild, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rémi</namePart><namePart type="family">Dendale</namePart><affiliation>Département de Radiothérapie, Institut Curie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Desjardins</namePart><affiliation>Département d'Ophtalmologie, Institut Curie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hui K</namePart><namePart type="family">Gan</namePart><affiliation>Austin-Ludwig Medical Oncology Department, Melbourne, Victoria, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="review-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>BMJ Publishing Group Ltd.</publisher><place><placeTerm type="text">BMA House, Tavistock Square, London, WC1H 9JR</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCreated encoding="w3cdtf">2010-12-22</dateCreated><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial cancer of the lacrimal gland. Despite a slow rate of growth, ACCs are ultimately associated with poor clinical outcome. Given the rarity of this disease, most recommendations regarding therapy are guided by expert opinion and retrospective data rather than level 1 evidence. Surgery and postoperative radiation therapy are commonly used as initial local treatment. In patients at high risk of recurrence, concomitant platinum-based chemotherapy may be added to postoperative radiotherapy in an attempt to enhance radio-sensitivity. While encouraging responses have been reported with intra-arterial neoadjuvant chemotherapy, this strategy is associated with substantial toxicity and should be considered investigational. For patients with metastatic disease not amenable to surgery or radiotherapy, chemotherapy may have a role based on its modest efficacy in non-lacrimal ACC. Similarly, molecular targeted agents may have a role, although the agents tested to date in non-lacrimal ACC have been disappointing. A better understanding of the biology of ACC will be crucial to the future success of developing targeted agents for this disease.</abstract><subject><genre>keywords</genre><topic>Adenoid cystic carcinoma</topic><topic>lacrimal gland</topic><topic>targeted therapy</topic><topic>chemotherapy</topic><topic>microbiology</topic><topic>treatment medical</topic></subject><relatedItem type="host"><titleInfo><title>British Journal of Ophthalmology</title></titleInfo><titleInfo type="abbreviated"><title>Br J Ophthalmol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0007-1161</identifier><identifier type="eISSN">1468-2079</identifier><identifier type="PublisherID">bjo</identifier><identifier type="PublisherID-hwp">bjophthalmol</identifier><identifier type="PublisherID-nlm-ta">Br J Ophthalmol</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1483</start></extent></part></relatedItem><identifier type="istex">A98138A4D9375D8FFEF3D33B382D44F5404C7005</identifier><identifier type="ark">ark:/67375/NVC-5FR75XLX-Z</identifier><identifier type="DOI">10.1136/bjo.2010.192351</identifier><identifier type="href">bjophthalmol-95-1483.pdf</identifier><identifier type="ArticleID">bjophthalmol192351</identifier><identifier type="PMID">21183517</identifier><identifier type="local">bjophthalmol;95/11/1483</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/A98138A4D9375D8FFEF3D33B382D44F5404C7005/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002021 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002021 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A98138A4D9375D8FFEF3D33B382D44F5404C7005
|texte= Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland
}}
| This area was generated with Dilib version V0.6.33. |  |